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Abstract
Background: KIR2DS5 gene encodes an activating natural killer cell receptor whose ligand is not known. It was recently
reported to affect the outcome of hematopoietic stem cell transplantation.
Methodology/Principal Findings: In our studies on KIR2DS5 gene associations with human diseases, we compared the
frequencies of this gene in patients and relevant controls. Typing for KIR2DS5 gene was performed by either individual or
multiplex polymerase chain reactions which, when compared in the same samples, gave concordant results. We noted an
apparently protective effect of KIR2DS5 gene presence in several clinical conditions, but not in others. Namely, this effect
was observed in ankylosing spondylitis (p=0.003, odds ratio [OR]=0.47, confidence interval [CI]=0.28–0.79), endometriosis
(p=0.03, OR=0.25, CI=0.07–0.82) and acute rejection of kidney graft (p=0.0056, OR=0.44, CI=0.24–0.80), but not in non-
small-cell lung carcinoma, rheumatoid arthritis, spontaneous abortion, or leukemia (all p.0.05). In addition, the
simultaneous presence of KIR2DS5 gene and HLA-C C1 allotype exhibited an even stronger protective effect on ankylosing
spondylitis (p=0.0003, OR=0.35, CI=0.19–0.65), whereas a lack of KIR2DS5 and the presence of the HLA-C C2 allotype was
associated with ankylosing spondylitis (p=0.0017, OR=1.92, CI=1.28–2.89), whereas a lack of KIR2DS5 and presence of C1
allotype was associated with rheumatoid arthritis (p=0.005, OR=1.47, CI=1.13–1.92). The presence of both KIR2DS5 and C1
seemed to protect from acute kidney graft rejection (p=0.017, OR=0.47, CI=0.25–0.89), whereas lack of KIR2DS5 and
presence of C2 seemed to favor rejection (p=0.0015, OR=2.13, CI=1.34–3.37).
Conclusions/Significance: Our results suggest that KIR2DS5 may protect from endometriosis, ankylosing spondylitis, and
acute rejection of kidney graft.
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Introduction
Killer immunoglobulin-like two-domain short-tail receptor 5
(KIR2DS5) is a member of a large KIR family of cell-surface
receptors expressed on natural killer (NK) cells and subpopulations
of T lymphocytes. In contrast to long cytoplasmic tail-possessing
KIRs (KIR2DL and KIR3DL), which inhibit cell activation upon
ligand binding, KIRs with short cytoplasmic tails (KIR3DS1 and
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12381KIR2DS, including KIR2DS5) activate cells expressing them.
Ligands (HLA class I molecules) are known only for some KIRs
(HLA-C alleles from the C1 group [Asn80] for KIR2DL2 and
KIR2DL3; HLA-C alleles from the C2 group [Lys80] for
KIR2DL1 and KIR2DS1; HLA-B from the Bw4 group for
KIR3DL1 and possibly KIR3DS1; HLA-A*03, *11 for KIR3DL2),
whereas no physiological ligands are known for the remaining
KIRs, including KIR2DS5 [1,2]. Nevertheless, the effects of
KIR2DS5 gene presence or absence in the context of HLA-C C1
or C2 or both were recently observed in bone marrow
transplantation [3]. Upon our studies on the associations of KIR
genes with a panel of autoimmune, gynecological, and neoplastic
diseases as well as in the acute rejection of kidney graft, we observed
effects of KIR2DS5 gene and HLA-C C1 and C2 groups in some of
these clinical situations. A protective effect of KIR2DS5 gene on
susceptibility to psoriasis vulgaris was already described elsewhere
[4]. Other results are presented here.
Results
The frequencies of KIR2DS5 gene in autoimmune and
neoplastic diseases as well as in renal transplant rejection were
compared with its frequency in a representative population of 690
healthy unrelated Poles (Control I, see Materials and Methods).
Significant differences were found in only two clinical situations,
ankylosing spondylitis (AS) and acute rejection of kidney graft
(Table 1). In both instances a decrease in KIR2DS5 frequency was
observed. However, only AS result was still significant after
Bonferroni correction (pc=0.033). No significance was found in
comparisons between controls (Control I) and patients with
rheumatoid arthritis (RA), stable kidney graft function, and
neoplastic diseases such as non-small-cell lung carcinoma
(NSCLC), acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), and chronic myeloid leukemia (CML).
KIR2DS5 frequency in endometriosis was compared with that in
healthy women who had delivered at least one healthy baby
(Control II). Again, it was less frequent in the patients than in the
controls (Table 1).
Women suffering from spontaneous abortion were compared
with healthy women who had delivered at least two healthy
children (Control III). No significant difference between these two
groups was detected in frequencies of KIR2DS5 gene (Table 1).
HLA-C C1 and C2 phenotype and genotype frequencies were
significantly different from controls in ankylosing spondylitis (i.e. a
decrease in C1 frequency) (Table 2). Moreover, C1C2 heterozy-
gosity was less frequent in non-small-cell lung carcinoma patients
(significant difference from the control, Table 2). However, both
differences lost significance after correction.
In addition, the analysis of combinations of the presence of
KIR2DS5 with the two HLA-C groups revealed several interesting
results (see Table 3 for raw data and Table 4 for statistical
analysis). In KIR2DS5-positive AS patients the frequencies of the
HLA-C C1 phenotype were significantly lower than in Control I,
and this was the only result in Table 4 which persisted significant
after correction (pc=0.033). In AS, the C1C2 genotype was three
times less frequent than in the controls. In contrast, the C2
phenotype frequency was decreased in endometriosis in compar-
ison with Control II.
Similarly, in the absence of KIR2DS5, the C1 and C2
phenotypes were significantly associated with several clinical
conditions. Thus C1 frequencies were increased in RA and kidney
graft rejection, whereas those of C2 were increased in AS, and
kidney rejection. C1C2 heterozygosity was increased in RA and
kidney rejection.
No differences in the distributions of C1 and C2 phenotypes
and genotypes combined with the presence or absence of KIR2DS5
were observed in kidney graft nonrejectors (Tables 3 and 4) or
patients with malignancies (ALL, AML, CML, and NSCLC; data
Table 1. Frequencies of KIR2DS5 gene in different diseases.
Group N % (positive) p value Odds ratio Confidence intervals Statistical power (%)****
Control I* 690 29.7 (205)
Control II** 213 31.9 (68)
Control III*** 117 31.6 (37)
Patients group vs Control I
Ankylosing spondylitis 115 16.5 (19) 0.003 0.47 0.28–0.79 87
Rheumatoid arthritis 366 24.3 (89) 0.07 0.76 0.57–1.02 46
Non-small cell lung carcinoma 280 25.7 (72) .0.05 - - 24
Acute lymphoblastic leukemia 22 23.8 (5) .0.05 - - 13
Acute myeloid leukemia 40 32.5 (13) .0.05 - - 11
Chronic myeloid leukemia 34 35.3 (12) .0.05 - - 18
Acute rejection of kidney graft 89 15.7 (14) 0.0056 0.44 0.24–0.80 91
Stable kidney graft function 196 26.0 (51) .0.05 - - 26
Patients group vs Control II
Endometriosis 153 21.6 (33) 0.03 0.25 0.07–0.82 28
Patients group vs Control III
Spontaneous abortion 149 26.2 (39) .0.05 - - 25
*healthy volunteers, including both groups listed below;
**healthy fertile women;
***women with two or more healthy-born children with the same partner and no history of abortion.
****statistical power was calculated post-hoc for alpha error level=0.05.
doi:10.1371/journal.pone.0012381.t001
KIR2DS5 Gene and Human Disease
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12381not shown). The same was true for spontaneous abortion couples
compared with Control III (data not shown).
Discussion
Our results suggest that the presence of KIR2DS5 gene may
protect against some clinical conditions. In addition to psoriasis
vulgaris described earlier [4], such protection was observed in
endometriosis, ankylosing spondylitis, and acute rejection of
kidney graft. In women with endometriosis, in contrast to healthy
ones, ectopic endometrium is thought to be inefficiently eliminated
by NK cells which exhibit insufficient cytotoxic activity in these
patients [5,6]. Therefore, a contribution of activating KIR2DS5
receptor to protection against endometriosis seems likely.
In contrast, an explanation of the apparently paradoxical
protective effect of a killer cell-activating receptor in autoimmune
disease (ankylosing spondylitis) and acute transplant rejection is
more difficult. NK cells have been postulated to contribute to
allograft tolerance induction [7,8]. Therefore we may speculate
that the presence of KIR2DS5 contributes to the activation of NK
cells, leading to a more efficient induction of tolerance and
inhibition of allograft rejection and autoimmunity. In contrast,
lack of KIR2DS5 would weaken NK cell activation, resulting in
insufficient induction of tolerance and in the promotion of acute
kidney allograft rejection or autoaggression, for example in
ankylosing spondylitis. It should be noted here, however, that in
HLA-B27-positive Chinese patients with ankylosing spondylitis,
KIR2DS5 was associated rather with susceptibility than with
protection compared with HLA-B27-positive controls [9], whereas
it was not associated with this disease in HLA-unselected Chinese
patients compared with unselected controls [10]. However,
Chinese are genetically distant from Caucasians, as reflected, for
example, by the difference in distribution of HLA-B27 subtypes
(alleles) in these two populations [11,12], and indeed, neither
KIR3DL1/KIR3DS1 [13] nor KIR2DS5 [9] effects on AS in
Chinese could be reproduced in some Caucasian populations [14],
although they were observed in other Caucasians [15,16]. In our
study, we have not seen any association of KIR3DL1, putative
receptor of HLA-B27 [17,18], and only weak association of
KIR3DS1, with ankylosing spondylitis (data not shown). This may
speak against linkage disequilibrium (LD) of KIR2DS5 with other
KIRs as a main cause of its protective effect in AS.
One might argue that the apparent effect of KIR2DS5 in other
diseases might be caused by its LD with other KIR2D genes whose
products bind HLA-C molecules, distinguishing between C1 and
C2 epitopes [1,2]. Indeed, kidney graft rejection seems to be
Table 2. Frequencies of HLA-C C1 and C2 gene groups in different diseases.
HLA-C
Controls I
(N=680)
Controls II
(N=213)
AS*
(N=115)
RA*
(N=366)
E**
(N=153)
KGR*
(N=89)
KGNR
(N=196)
ALL
(N=21)
AML
(N=39)
CML
(N=33)
NSCLC
(N=269)
C1 83.7 (569) 82.2 (175) 73.9 (85)
a 88.3 (323) 82.4 (126) 83.1 (74) 84.2 (165) 71.4 (15) 76.9 (30) 75.8 (25) 79.9 (215)
C2 67.2 (457) 64.8 (138) 74.8 (86) 69.1 (253) 60.1 (92) 75.3 (67) 66.3 (130) 76.2 (16) 59.0 (23) 63.6 (21) 61.0 (164)
C1C1 32.8 (223) 35.2 (75) 25.2 (29) 30.9 (113) 39.9 (61) 24.7 (22) 33.7 (66) 23.8 (5) 41.0 (16) 36.4 (12) 39.0 (105)
C2C2 16.3 (111) 17.8 (38) 26.1 (30)
b 11.7 (43) 17.6 (27) 16.9 (15) 15.8 (31) 28.6 (6) 23.1 (9) 24.2 (8) 20.1 (54)
C1C2 50.9 (346) 46.9 (100) 48.7 (56) 57.4 (210) 42.5 (65) 58.4 (52) 50.5 (99) 47.6 (10) 35.9 (14) 39.4 (13) 40.9 (110)
c
AS, ankylosing spondylitis; RA, rheumatoid arthritis; E, endometriosis; KGR, kidney graft rejectors; KGRN, kidney graft non-rejectors; ALL, acute lymphoblastic leukemia;
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NSCLC, non-small cell lung carcinoma; Control I, healthy volunteers; Control II, healthy fertile women;
*compared to Control I; **compared to Control II.
ap=0.02 OR=0.55 95%CI 0.35–0.88.
bp=0.02 OR=1.81 95%CI 1.14–2.89.
cp=0.006 OR=0.67 95%CI 0.50–0.89.
doi:10.1371/journal.pone.0012381.t002
Table 3. Frequencies of KIR2DS5 gene and C1 and C2 groups of HLA-C in several human diseases and healthy control individuals.
2DS5 HLA-C
Controls I
(N=680)
Controls II
(N=213) AS* (N=115) RA* (N=366) E** (N=153) KGR* (N=89)
KGNR*
(N=196)
NSCLC*
(N=269)
+ C1 25.1 (171) 25.5 (54) 10.4 (12) 20.8 (76) 18.3 (28) 13.5 (12) 21.4 (42) 21.6 (58)
+ C2 19.7 (134) 23.5 (50) 11.3 (13) 16.4 (60) 11.1 (17) 10.1 (9) 16.8 (33) 15.2 (41)
+ C1C1 9.8 (67) 8.5 (18) 5.2 (6) 7.9 (29) 10.5 (16) 5.6 (5) 9.2 (18) 10.8 (29)
+ C2C2 4.4(30) 6.6 (14) 6.1 (7) 3.6 (13) 3.3 (5) 2.2 (2) 4.6 (9) 4.5 (12)
+ C1C2 15.3 (104) 16.9 (36) 5.2 (6) 12.8 (47) 7.8 (12) 7.9 (7) 12.2 (24) 10.8 (29)
- C1 58.4 (398) 56.8 (121) 63.5 (73) 67.5 (247) 64.1 (98) 69.7 (62) 62.8 (123) 58.4 (157)
- C2 47.6 (323) 41.3 (88) 63.5 (73) 52.7 (193) 49.0 (75) 65.2 (58) 49.5 (97) 45.7 (123)
- C1C1 22.9 (156) 26.8 (57) 20.0 (23) 23.0 (84) 29.4 (45) 19.1 (17) 24.5 (48) 28.3 (76)
- C2C2 11.9 (81) 11.3 (24) 20.0 (23) 8.2 (30) 14.4 (22) 14.6 (13) 11.2 (22) 15.6 (42)
- C1C2 35.5 (242) 30.1 (64) 43.5 (50) 44.5 (163) 34.6 (53) 50.6 (45) 38.3 (75) 30.1 (81)
AS, ankylosing spondylitis; RA, rheumatoid arthritis; E, endometriosis; KGR, kidney graft rejectors; KGRN, kidney graft non-rejectors; NSCLC, non-small cell lung
carcinoma; Control I, healthy volunteers; Control II, healthy fertile women.
doi:10.1371/journal.pone.0012381.t003
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data), which is in negative LD with KIR2DS5 in many human
populations including European Caucasians [19]. Therefore, the
apparent protective effect of KIR2DS5 described here for kidney
rejection may result from this LD. On the other hand, only
KIR2DS5 gene was (negatively) associated with susceptibility to
endometriosis, and KIR2DS4 deletion variant was less frequent in
peritoneal form of this disease (our unpublished data). This finding
speaks against LD as an explanation for KIR2DS5 protective effect
in endometriosis because KIR2DS4 and KIR2DS5 are mutually
exclusive in most haplotypes [19].
We also observed effects of HLA-C C1 and C2 genotypes in
some diseases. We found an association with C2 homozygosity in
ankylosing spondylitis, which seems to be concordant with results
in Chinese, where an association of the HLA-Cw*02 allele (a
member of the C2 group) with this disease was described [9]. We
can not exclude LD of C2 with HLA-B27 as a main cause of this
association, as most HLA-B*27 carriers in Caucasian populations
have HLA-Cw*02 [20]. Another finding was that C1C2
heterozygosity seemed to protect from NSCLC. Although no
data have been published on an association between NSCLC and
HLA-C so far, we may speculate that the C1C2 genotype may
allow for a wider spectrum of KIRs to contribute to control over
cancer cells.
Additionally, we observed that in some diseases, the effect of C1
and C2 phenotypes or genotypes seemed to be detectable only in
the absence of KIR2DS5 gene but was visible only in its presence in
other diseases. However, these results are easily explainable by the
protective effect of KIR2DS5 alone. For example, both the C1 and
the C2 frequencies were reduced in AS patients positive for
KIR2DS5, whereas both were increased in KIR2DS5-negative
patients.
In summary, our results suggest protective effect of the presence
of KIR2DS5 gene in ankylosing spondylitis, endometriosis and
acute kidney graft rejection, independent from HLA-C. Some
KIR2DS5-independent associations of ankylosing spondylitis and
NSCLC with HLA-C C1 and/or C2 groups are also reported here.
To our knowledge, this is the first report on possible associations of
non-small cell lung cancer with KIR and HLA-C genes.
Materials and Methods
Participants
Three hundred and sixty-six patients with rheumatoid arthritis
(280 women, 64 men; mean age, 57.8612.3, range 22–90) were
recruited from the inpatient and outpatient population of the
Clinic of Rheumatology and Internal Diseases, Autonomous
Public Clinical Hospital No. 1, Pomeranian Medical University
in Szczecin, Poland, and diagnosed according to the criteria of the
American College of Rheumatology as described previously [21].
Two hundred and eighty patients (80 women and 200 men,
mean age 62.0669.3, range 35–87 years) with pathologically
documented non-small-cell lung carcinoma (NSCLC) were
qualified in the Department of Pulmonology and Lung Cancer,
Wroclaw Medical University, and in the Clinic of Lung and
Thorax Neoplasms, Centre of Oncology – Maria Skłodowska-
Curie Institute, Warsaw. The diagnosis of lung cancer was based
on positive histological or cytological examination (according to
WHO criteria) [22]. A fibro-bronchoscopic examination was
performed in all the patients, with harvesting of material for
histological and cytological examination for establishing a
diagnosis of NSCL. All participants underwent a sputum cytology
survey as well. Advancement of the disease was determined
according to the TNM staging system; thoracic computed
tomography involving the upper abdomen was used for this
purpose.
Two hundred and eighty-five adult cadaveric donor renal
transplant recipients (123 women, 162 men; mean age,
43.43611.44 years, range, 15–72) from the Department of
Nephrology and Transplantation Medicine, Wrocław Medical
University, who had undergone primary transplantation between
1989 and 2008 were included in the study; mean time of follow-up
was 7 years. All patients received conventional immunosuppres-
sion: cyclosporine or tacrolimus in combination with azathioprine
or mycofenolate mofetil and steroids. They were divided into two
groups according to the occurrence of an acute rejection episode:
89 patients with an acute rejection episode and 196 patients
without. Acute rejection was defined by an increase in serum
creatinine level of at least 20% above the baseline measurements
(not attributable to another cause) and confirmed by biopsy
according to the Banff histopathological criteria [23]. Apart from
three patients, all had a biopsy-confirmed acute rejection episode.
One hundred and fifteen patients (18 women, 83 men; age data
for 101 patients were available: mean age, 36.7614.5 years; range,
18–71) were diagnosed as definite ankylosing spondylitis in
accordance with the modified New York classification criteria
[24] at the Department of Rheumatology III, Silesian Hospital of
Rheumatology and Rehabilitation, Ustron ´, or at the Department
and Clinic of Rheumatology and Internal Medicine, Wrocław
Medical University. Ninety percent of the patients were HLA-
B*27 positive by either serological or genetic typing (data not
shown), in agreement with other populations [12].
Ninety-six patients treated with allogeneic hematopoietic stem
cell transplant in the Department of Hematology and Bone
Marrow Transplantation of the Silesian Medical University in
Katowice because of leukemia (53 women, 43men; mean age,
33.3610.9 years; including acute lymphoblastic leukemia, ALL,
22 patients, 11 women, 11 men; mean age, 27.469.7; acute
myeloid leukemia, AML, 40 patients, 26 women, 14 men; mean
Table 4. Statistical analysis of the data from Table 3 (KIR2DS5,
C1 and C2 frequencies).
Comparison 2DS5 HLA-C p OR 95%CI Effect
AS vs Control I + C1 0.0003 0.35 0.19–0.65 Q
+ C2 0.037 0.52 0.28–0.95 Q
+ C1C2 0.003 0.31 0.13–0.71 Q
- C2 0.0017 1.92 1.28–2.89 q
- C2C2 0.024 1.85 1.11–3.09 q
RA vs Control I - C1 0.005 1.47 1.13–1.92 q
- C1C2 0.005 1.45 1.12–1.88 q
E vs Control II + C2 0.0025 0.41 0.22–0.74 Q
+ C1C2 0.012 0.42 0.21–0.83 Q
KGR vs Control I + C1 0.017 0.47 0.25–0.89 Q
+ C2 0.04 0.47 0.23–0.95 Q
- C1 0.0088 1.89 1.18–3.05 q
- C2 0.0015 2.13 1.34–3.37 q
- C1C2 0.0051 1.89 1.21–2.95 q
KGR vs KGRN - C2 0.015 1.91 1.14–3.21 q
AS, ankylosing spondylitis; RA, rheumatoid arthritis; E, endometriosis; KGR,
kidney graft rejectors; KGRN, kidney graft non-rejectors; Control I, healthy
volunteers; Control II, healthy fertile women; q, susceptibility; Q, protection; p,
probanility; OR, odds ratio; 95% CI, 95% confidence interval.
doi:10.1371/journal.pone.0012381.t004
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women, 18 men; mean age, 33.1 years) were described elsewhere
[25].
Six hundred and ninety unrelated healthy volunteers (355
women, 335 men; mean age, 38.62614.60, range, 19–56) were
recruited in the years 2001–2008 by the Regional Center of Blood
Transfusion, Wrocław, as well as by clinics of the Wrocław
Medical University, the Medical University of Warsaw, and the
Pomeranian Medical University, Szczecin (Control I, used for the
diseases mentioned above).
One hundred and fifty-three women with endometriosis (mean
age 33.768.0, range 20–58 years) diagnosed at the First and
Second Departments of Obstetrics and Gynecology, Medical
University of Warsaw, for pelvic pains, dysmenorrhea, and/or
infertility were described in detail elsewhere [26]. Endometriosis
had been confirmed and classified in these patients by both
laparoscopic and histopathological examinations according to the
revised American Fertility Society criteria [27]. Two hundred and
thirteen healthy women who had given birth to at least one child
were used as a control (Control II; this group included women
from Control III described below and was included in Control I).
One hundred forty-nine couples (mean age of women:
32.4464.21 years, range: 24–46) who had experienced spontane-
ous abortion (SA) were recruited for our study at the Polish
Mother’s Memorial Hospital - Research Institute, Ło ´dz ´, the First
Chair and Clinic of Obstetrics and Gynecology, Medical
University of Warsaw, and the Institute of Human Genetics,
Polish Academy of Sciences, Poznan ´. The criteria for patient
classification and inclusion were presented elsewhere [28]. For a
control (‘‘Control III’’), 117 healthy couples (mean age of women:
31.3766.36, range: 23–68 years) with at least two healthy-born
children and no history of abortion were included (Wrocław
Medical University and Medical University of Warsaw).
DNA isolation and KIR2DS5 and HLA-C C1/C2 group
typing
Genomic DNA was isolated from venous blood as described
elsewhere [21,29]. KIR2DS5 was typed by either individual [29] or
multiplex [30] polymerase chain reactions which, when compared
in the same samples, gave concordant results. It should be noted
here that our KIR typing is validated three times per year by the
International KIR Exchange program organized by the Immu-
nogenetics Center of the University of California at Los Angeles.
HLA-C groups C1 and C2 were established as described by Frohn
et al. [31].
Ethics
This project was accepted by the Bioethics Committee of the
Medical University of Warsaw, the Bioethics Committee of
the Wrocław Medical University, the Bioethics Committee of
the Pomeranian Medical University in Szczecin, the Bioethics
Committee of the Polish Mother’s Memorial Hospital - Research
Institute in Ło ´dz ´, the Bioethics Committee of the Silesian Medical
University in Katowice, and the Bioethics Committee of the
Medical University of Poznan ´. Signed informed consent was given
by all participants. Ludwik Hirszfeld Institute of Immunology and
Experimental Therapy has no Bioethic Committee for research on
human materials, and our projects are evaluated by the Bioethics
Committee of the Wrocław Medical University. The same applies
to the Silesian Hospital of Rheumatology and Rehabilitation
which needs approval from the Bioethics Committee of the
Silesian Medical University in Katowice. Approval from the
Bioethics Committee of the Institute of Oncology in Gliwice was
not required, as no samples originated from that institution.
Statistical methods
Differences between controls, patients, and patient subgroups
were estimated using the two-tailed Fisher’s exact test and
GraphPad InStat 3 software. A p value,0.05 was considered
significant. The Bonferroni correction of p-values (if,0.05) was
calculated for the number of comparisons (11 for Table 1, 45 for
Table 2, and 70 for Table 3). Statistical power was calculated post-
hoc for alpha error level=0.05.
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